Sign In
Buy BRM
Bristol-Myers Squibb Company Earnings Calls
| Release date | Oct 30, 2025 |
| EPS estimate | 1.29€ |
| EPS actual | 1.39€ |
| EPS Surprise | 7.75% |
| Revenue estimate | 12.251B |
| Revenue actual | 10.416B |
| Revenue Surprise | -14.98% |
| Release date | Jul 31, 2025 |
| EPS estimate | 0.93€ |
| EPS actual | 0.545€ |
| EPS Surprise | -41.14% |
| Revenue estimate | 11.726B |
| Revenue actual | 10.421B |
| Revenue Surprise | -11.12% |
| Release date | Apr 24, 2025 |
| EPS estimate | 1.38€ |
| EPS actual | 1.10€ |
| EPS Surprise | -20.29% |
| Revenue estimate | 11.31B |
| Revenue actual | 10.197B |
| Revenue Surprise | -9.84% |
| Release date | Feb 06, 2025 |
| EPS estimate | 1.41€ |
| EPS actual | 0.0342€ |
| EPS Surprise | -97.57% |
| Revenue estimate | 11.564B |
| Revenue actual | 11.919B |
| Revenue Surprise | 3.07% |
Last 4 Quarters for Bristol-Myers Squibb Company
Below you can see how BRM.DE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 06, 2025 |
| Price on release | 56.79€ |
| EPS estimate | 1.41€ |
| EPS actual | 0.0342€ |
| EPS surprise | -97.57% |
| Date | Price |
|---|---|
| Jan 31, 2025 | 57.11€ |
| Feb 03, 2025 | 58.25€ |
| Feb 04, 2025 | 57.11€ |
| Feb 05, 2025 | 57.27€ |
| Feb 06, 2025 | 56.79€ |
| Feb 07, 2025 | 54.74€ |
| Feb 10, 2025 | 54.01€ |
| Feb 11, 2025 | 54.08€ |
| Feb 12, 2025 | 53.66€ |
| 4 days before | -0.560% |
| 4 days after | -5.51% |
| On release day | -3.61% |
| Change in period | -6.04% |
| Release date | Apr 24, 2025 |
| Price on release | 42.60€ |
| EPS estimate | 1.38€ |
| EPS actual | 1.10€ |
| EPS surprise | -20.29% |
| Date | Price |
|---|---|
| Apr 16, 2025 | 43.88€ |
| Apr 17, 2025 | 43.60€ |
| Apr 22, 2025 | 43.32€ |
| Apr 23, 2025 | 42.29€ |
| Apr 24, 2025 | 42.60€ |
| Apr 25, 2025 | 41.50€ |
| Apr 28, 2025 | 42.54€ |
| Apr 29, 2025 | 42.80€ |
| Apr 30, 2025 | 43.90€ |
| 4 days before | -2.92% |
| 4 days after | 3.05% |
| On release day | -2.58% |
| Change in period | 0.0456% |
| Release date | Jul 31, 2025 |
| Price on release | 38.44€ |
| EPS estimate | 0.93€ |
| EPS actual | 0.545€ |
| EPS surprise | -41.14% |
| Date | Price |
|---|---|
| Jul 25, 2025 | 40.53€ |
| Jul 28, 2025 | 41.23€ |
| Jul 29, 2025 | 40.74€ |
| Jul 30, 2025 | 40.67€ |
| Jul 31, 2025 | 38.44€ |
| Aug 01, 2025 | 37.77€ |
| Aug 04, 2025 | 38.54€ |
| Aug 05, 2025 | 39.08€ |
| Aug 06, 2025 | 39.03€ |
| 4 days before | -5.14% |
| 4 days after | 1.53% |
| On release day | -1.74% |
| Change in period | -3.69% |
| Release date | Oct 30, 2025 |
| Price on release | 38.92€ |
| EPS estimate | 1.29€ |
| EPS actual | 1.39€ |
| EPS surprise | 7.75% |
| Date | Price |
|---|---|
| Oct 24, 2025 | 37.70€ |
| Oct 27, 2025 | 37.23€ |
| Oct 28, 2025 | 37.02€ |
| Oct 29, 2025 | 36.92€ |
| Oct 30, 2025 | 38.92€ |
| Oct 31, 2025 | 39.96€ |
| Nov 03, 2025 | 39.75€ |
| Nov 04, 2025 | 40.21€ |
| Nov 05, 2025 | 39.66€ |
| 4 days before | 3.24% |
| 4 days after | 1.90% |
| On release day | 2.66% |
| Change in period | 5.20% |
Bristol-Myers Squibb Company Earnings Call Transcript Summary of Q3 2025
Bristol-Myers Squibb reported a strong Q3 2025 driven by its growth portfolio (up 17% YoY) with notable momentum from Opdivo/Qvantig, Reblozyl, Camzyos, Breyanzi and early-stage launches Cobenfy and Qvantig. The company raised full-year revenue guidance by $750M (new range $47.5B–$48.0B) while keeping the EPS midpoint unchanged due to net acquired in‑process R&D and licensing charges; non‑GAAP EPS guidance narrowed to $6.40–$6.60. BMS highlighted multiple near‑term and 2026 data catalysts (including ADEPT-2 Cobenfy readout by year-end, Phase III EXCALIBER iberdomide MRD result, milvexian programs and several pivotal pumitamig studies with BioNTech) and said pivotal readouts will accelerate in 2026. The company reiterated disciplined cost management and a $1B+ productivity program (line of sight to $2B by 2027), posted strong cash flow (~$6.3B in Q3) and continued debt paydown ($6.7B of $10B committed). Business development activity remains active (Orbital acquisition, PhiloChem license, SystImmune milestone), and management emphasized focus on execution, integration of digital/AI, and advancing several transformational platforms (protein degradation, radiopharmaceuticals, cell therapy for autoimmune disease).
